RWE56 - Why sample size matters

Why sample size matters

1000 patient record study with Cancer Electronic Prescribing Records (EPRs), the data source for SACT. RWE to be used in improving patient care. Click here to see the source article    About SVMPharma SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online […]

Read More
RWE55 - FDA encourages RWE in oncology

FDA encourages RWE in oncology

RWE can provide deep and accurate real-world clinical evidence, providing useful data for the increasingly stratified molecular subtypes of cancer “When we enable oncologists to see patient data clearly, we can make sure that everyone touched by cancer finds the right path to the right care.” Click here to see the source article    About SVMPharma SVMPharma is an […]

Read More
RWE54 - RWE highlights treatment gaps in Major Depressive Disorder patients

RWE highlights treatment gaps in Major Depressive Disorder patients

“Data Presented at the American Psychiatric Association 2019 Meeting Suggest a Low Rate of Psychiatric Care Received by Adult Patients with MDD Before Suicide Ideation or Attempt Diagnosis” “Additional Data Show Patients Have a High Risk of Hospital Readmission or Subsequent Emergency Department Visit after Suicide Ideation or Attempt” Click here to see the source article  About SVMPharma SVMPharma […]

Read More
RWE53

Leveraging RWD to improve regulatory decisions

How real world evidence was used to support approval of Ibrance for male breast cancer “Leveraging RWD to improve regulatory decisions is a key strategic priority for the FDA. This data may be derived from a variety of sources, such as electronic health records, medical claims, product and disease registries, laboratory test results and even […]

Read More
Slide1

In the era of cell and gene therapy, how robust is RWE collection?

  “Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching” “Existing data collection infrastructure in indications with potential cell or gene therapies launches in the next five years in the UK is overall not sufficient to facilitate outcomes-based reimbursement.” Click here to see the source article  Reference Jørgensen, J., […]

Read More
FINAL RWE49

RWE improving asthma outcomes

5.4 million people in the UK are currently affected by asthma 3 three year projects will be taking place in Manchester, Edinburgh and Portsmouth respectively Each project set to receive more than £200,000 from innovate and Asthma UK Click here to see the source article  Reference GOV.UK. (2019). Better, faster, more personalised asthma treatment. [online] Available at: https://www.gov.uk/government/news/better-faster-more-personalised-asthma-treatment [Accessed 28 […]

Read More
FINAL RWE48

RCT outcomes predicted by RWE

FDA and Brigham and Women’s Hospital have expanded their previous RCT DUPLICATE demonstration project to predict the results of seven Phase IV trails that are currently ongoing Part of the project will estimate the results of randomised controlled trials before they are finished with the use of RWE Click here to see the source article  Reference Hale, C. (2019). Using […]

Read More
FINAL RWE47

RWE can accelerate the pace of discovery of new oncology therapies

Companies and HTA bodies are looking at real-world evidence to inform reimbursement of novel cancer therapies like CAR-T Click here to see the source article  Reference Be The Match BioTherapies. (2019). CIBMTR to Track Long-Term Outcomes Data for Kymriah®. [online] Available at: https://bethematchbiotherapies.com/newsroom/cibmtr-to-track-long-term-outcomes-data-for-kymriah/ [Accessed 23 Apr. 2019].   About SVMPharma SVMPharma is an innovative strategic consultancy, specialising in Real World […]

Read More
FINAL RWE46

RWE Challenges and Misconceptions

A look into the 5 common myths for the adaption of patient-reported RWE for devices, these include Age as a barrier to technology HCP reluctance to adopting new technology Sharing of health data Clinical trial compliance The readiness of device platforms Click here to see the source article  Reference Hellman B. Real-World-Evidence Mythbusting: 5 myths holding back patient-reported RWE […]

Read More